Antiproliferative activity of Titanocene Y against tumor colony-forming units
Oberschmidt, O., Hanauske, A.R., Pampillón, C., Strohfeldt, K., Sweeney, N.J. and Tacke, M. (2007) Antiproliferative activity of Titanocene Y against tumor colony-forming units. Anticancer Drugs, 18 (3). pp. 317-322. ISSN 0959-4973
Full text not archived in this repository.
To link to this article DOI: 10.1097/CAD.0b013e3280115f86
Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride, better known as Titanocene Y, is a newly synthesized titanium-based anticancer drug. We studied the antitumor activity of Titanocene Y with concentrations of 2.1, 21 and 210 μmol/l against a range of freshly explanted human tumors, using an in-vitro soft agar cloning system. The sensitivity against Titanocene Y was highly remarkable in the case of renal cell, ovarian, nonsmall cell lung and colon cancer. In particular the surprisingly good response of nonsmall cell lung cancer and colon cancer against Titanocene Y at its lowest concentration of 2.1 μmol/l was well comparable or better with respect to cisplatin, given at a concentration of 1.0 μmol/l. Further clinical development of Titanocene Y appears to be warranted because of the broad cytotoxic activity shown and the specific activity of Titanocene Y against renal cell cancer.
Centaur Editors: Update this record